Krystal Biotech Stock Forecast

Stock Price Forecast

The 10 analysts with 12-month price forecasts for Krystal Biotech stock have an average target of 297.6, with a low estimate of 176 and a high estimate of 371. The average target predicts an increase of 10.52% from the current stock price of 269.27.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$176	$297.6	$318	$371
Change	-34.64%	+10.52%	+18.10%	+37.78%

* Price targets were last updated on Feb 25, 2026.

Analyst Ratings

The average analyst rating for Krystal Biotech stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26
Strong Buy	6	6	8	9	9	9
Buy	1	1	1	0	0	0
Hold	2	2	1	1	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	9	9	10	10	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kalpit Patel Wolfe Research	Wolfe Research	Hold Initiates n/a	Hold	Initiates	n/a	n/a	Mar 27, 2026
Debjit Chattopadhyay Guggenheim	Guggenheim	Strong Buy Maintains $224 → $284	Strong Buy	Maintains	$224 → $284	+5.47%	Feb 25, 2026
Yigal Nochomovitz Citigroup	Citigroup	Strong Buy Maintains $336 → $371	Strong Buy	Maintains	$336 → $371	+37.78%	Feb 18, 2026
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $220 → $323	Strong Buy	Maintains	$220 → $323	+19.95%	Feb 18, 2026
Roger Song Jefferies	Jefferies	Strong Buy Maintains $310 → $371	Strong Buy	Maintains	$310 → $371	+37.78%	Feb 17, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

539.86M

from 389.13M

38.74%

from 389.13M

Revenue Next Year

715.45M

from 539.86M

32.53%

from 539.86M

EPS This Year

7.79

from 6.84

13.83%

from 6.84

EPS Next Year

10.84

from 7.79

39.24%

from 7.79

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	50.70M	290.52M	389.13M	539.86M	715.45M
Revenue Growth	-	-	-	473.02%	33.95%	38.74%	32.53%
EPS	-3.13	-5.49	0.39	3.00	6.84	7.79	10.84
EPS Growth	-	-	-	669.23%	128.00%	13.83%	39.24%
Forward PE	-	-	-	-	-	34.58	24.84
No. Analysts	-	-	-	-	-	14	12

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	631.9M	1.0B
Avg	539.9M	715.5M
Low	439.9M	571.1M

Revenue Growth

Revenue Growth	2026	2027
High	62.4%	91.0%
Avg	38.7%	32.5%
Low	13.1%	5.8%

EPS Forecast

EPS	2026	2027
High	10.07	20.91
Avg	7.79	10.84
Low	5.66	6.28

EPS Growth

EPS Growth	2026	2027
High	47.2%	168.5%
Avg	13.8%	39.2%
Low	-17.2%	-19.3%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.